Диссертация (1139499), страница 43
Текст из файла (страница 43)
[et al]// J Hum Hypertens. – 2014.– Vol.28(2). – P.85-91.203. Carey RM. Dopamine selectively inhibits aldosterone responses to angiotensin IIin humans./ Carey RM, Drake CR.// Hypertension. – 1986. – Vol.8. – P.399-406.274204. Carr M.C. The emergence of the metabolic syndrome with menopause./ CarrM.C. // J Clin Endocrinol Metab.
– 2003. – Vol.88(6). – P.2404-11.205. Ceconi C. ACE inhibition with perindopril and endothelial function. Results of asubstudy of the EUROPA study: PERTINENT./ Ceconi C, [et al]. // Cardiovascresearch. – 2007. – Vol.73. – P.237-46.206. Celec P. Dehydroepiandrosterone – is the fontain of the youth drying out?/ CelecP., Starca L. // Physiol Res. – 2003. – Vol.52. – P.397-407.207. Celentano A. Gender differences in left ventricular chamber and midwall systolicfunction in normotensive and hypertensive adults./ Celentano A.J. [et al].// Hypertens.
–2003. – Vol.21(7). – P.1415-23.208. Centerwel B.S. Premenopausal hysterectomy and cardiovascular disease./Centerwel B.S. // Am J Obstet Gynecol. – 1981. – Vol.139(1). – P.58-61.209. Chakrabarti S. Mechanisms of estrogen effects on the endothelium: an overview./Chakrabarti S., Morton JS, Davidge ST. // Can J Cardiol. – 2014. – Vol.30. – P.705-12.210.
Chasan-Taber L. Prospective Study of Oral Contraceptives and HypertensionAmong Women in the United States./ Chasan-Taber L., [et al].// Circulation. – 1996. –Vol.94. – P.483-489.211. Chen R.Y. Relative androgen deficiency in relation to obesity and metabolicstatus in older men./ Chen RY, Wittert GA, Andrews GR. // Diabetes Obes Metab.
–2006. – Vol.8(4). – P.429–35.212. Chester R. Women have significantly greater difference between central andperipheral arterial pressure compared with men: the Bogalusa Heart Study./ Chester R.[et al]// J Am Soc Hypertens. – 2013. – Vol.7(5). – P.379-85.213. Chien W.Y. Increased plasma concentration of nitric oxide in type 2 diabetes butnot in nondiabetic individuals with insulin resistance./ Chien W.Y. [et al].// DiabetesMetab. – 2005.
– Vol.31. – P.63–68.214. Chowdhary S. Nitric oxide and hypertension: not just an endothelium derivedrelaxing factor!/ Chowdhary S., Townend J.N. // J Human Hypertens. – 2001. – Vol.15.- P.219–227275215. Chowdhary S. Role of nitric oxide in the regulation of cardiovascular autonomiccontrol./ Chowdhary S, Townend JN. // Clin Sci. – 1999. – Vol.97. – P.5-17.216.
Chrysohoou C. Renal function, cardiovascular disease risk factors’ prevalenceand 5-year disease incidence: the role of diet, exercise, lipids and inflammationmarkers: the ATTICA study./ Chrysohoou C. [et al]./ Q.J.M. – 2010. – Vol.103. –P.413-422.217. Chung AK. Women have higher left ventricular ejection fractions than menindependent of differences in left ventricular volume: the Dallas Heart Study./ ChungAK, [et al].// Circulation. – 2006. – Vol.113(12). – P.1597–1604.218. Cockcroft JR. Preserved endothelium-dependent vasodilatation in patients withessential hypertension./ Cockcroft JR.
[et al]// N Engl J Med. – 1994. – Vol.330. –P.1036–1040.219. Coimbra R. Is gender crucial for cardiovascular adjustments induced by exercisetraining in female spontaneously hypertensive rats?/ Coimbra R. [et al]// Hypertension.– 2008. – Vol.52. – P.514-521.220. Colditz GA. Menopause and the risk of coronary heart disease in women./ ColditzGA. [et al]// N Engl J Med. – 1987. – Vol.316. – P.1105–10.221.
Collins P. Management of cardiovascular risk in the perimenopausal women: aconsensus statement of European cardiologist and gynaecologist./ Collins P. [et al].//Eur Heart J. – 2007. – Vol.28. – P.2028–4.222. Conroy RM. Estimation of ten-year risk of fatal cardiovascular disease in Europe:the SCORE project. / Conroy RM. [et al]. //Eur Heart J. - 2003.
- Vol.24. -Р.987-1003.223. Corona, G. Psychobiologic correlates of the metabolic syndrome and associatedsexual dysfunction./ Corona, G. et al. // Eur Urol. – 2006. – Vol.50. – P.595-604.224. Crawford MH. ACC/AHA guidelines for ambulatory electrocardiography: areport of the American College of Cardiology/ American Heart Association Task Forceon Practice Guidelines (Committee to Revise the Guidelines for AmbulatoryElectrocardiography)./ Crawford MH. [et al].// J Am Coll Cardiol. – 1999.
– Vol.34. –P.912-48.276225. Crawford MH. Task Force of the European Society of Cardiology and the NorthAmerican Society of Pacing and Electrophysiology. Heart rate variability: standards ofmeasurement, physiological interpretation, and clinical use./ Crawford MH. [et al]//Circulation. – 1996. – Vol.93. – P.1043– 65.226. Crews JK. Antagonistic effects of 17β-estradiol, progesterone, and testosteroneon Ca2+ entry mechanisms of coronary vasoconstriction./ Crews JK, Khalil RA.//Arterioscler Thromb Vasc Biol.
– 1999. – Vol.19(4). – P.1034-1040.227. Cucina A. Nicotine-induced smooth muscle cell proliferation is mediated throughbFGF and TGF-β./ Cucina A. [et al]//Surgery. – 2000. – Vol. 127. – P. 316-322.228. Dahlöf B. The Losartan Intervention For Endpoint reduction (LIFE) inHypertension study: rationale, design, and methods. The LIFE Study Group./ Dahlöf B.[et al].// Am J Hypertens. – 1997. – Vol.10. – P.705-13.229. Dannenburg A.
Impact of Age on Echocardiographic Left Ventricular Mass in aHealthy Population (The Framingham Heart Study)./ Dannenburg A, Levy D, GarrisonR.// Am J Cardiol. – 1989. – Vol.64(16). – P.1066–8.230. Daugherty SL. Sex differences in cardiovascular outcomes in patients withincident hypertension./ Daugherty SL. [et al]// J Hypertens. – 2013. – Vol.31(2). –P.271-7.231. Davis MD. Induction of tissue plasminogen activator mRNA and activity bystructurally altered estrogens./ Davis MD, Butler WB, Brooks SC. // J Steroid BiochemMol Biol. – 1995.
– Vol.52. – P.421-430.232. De Gasparo M. Angiotensin II and nitric oxide interaction./ De Gasparo M. //Heart Fail Res. – 2002. – Vol.7(4). – P.347-56.233. DeJongSC.Normohomocysteinaemiaandvitamintreatedhyperhomocysteinaemia are associated with similar risks of cardiovascular events inpatients with premature peripheral arterial occlusive disease. A prospective cohortstudy./ De Jong SC.
[et al]// J Intern Med. - 1999. – Vol.246. – P.87-96.234. De Nuccio I. Physiopathology of the renin-angiotensin system in the ovary./ DeNuccio I., [et al].// Minerva Endocrinol. – 1999. – Vol.24. – P.77-81.277235. De Pergola G. Influence of free testosterone on antigen levels of plasminogenactivator inhibitor 1 in premenopausal women with central obesity./ De Pergola G. [etal]// Metabolism.
– 1992. – Vol.41. – P.131-134.236. De Pergola G. Lower androgenicity is associated with higher plasma levels ofprothrombotic factors irrespective of age, obesity, body fat distribution, and relatedmetabolic parameters in men./ De Pergola G. [et al]// Metabolism.
-1997. –Vol.46(11).– P.1287-93.237. Dean SA. 17β-Estradiol downregulates tissue angiotensin-converting enzyme andANG II type 1 receptor in female rats./ Dean SA. [et al]// Am J Physiol Regul IntegrComp Physiol. – 2005. – Vol.288(3). – P.R759–R766.238. Deanfield JE.
Endothelial function and dysfunction: testingand clinicalrelevance./ Deanfield JE, Halcox JP, Rabelink TJ. // Circulation. – 2007. –Vol.115. –P.1285–95239. DeMaria J E. Ovarian steroids influence the activity of neuroendocrinedopaminergic neurons./ DeMaria J E, Livingstone J D, Freeman M E.
// Brain research.– 2000. – Vol.879(1-2). – P.139-47.240. Devereux RB. Echocardiographic determination of left ventricular mass in man:anatomic validation of the method./ Devereux RB, Reichek N. // Circulation. - 1997. –Vol.55. – P.613-618.241. Dhruva SS. Gender bias in studies for Food and Drug Administration premarketapproval of cardiovascular devices./ Dhruva SS, Bero LA, Redberg RF.//CircCardiovasc Qual Outcomes.
– 2011. – Vol.4. – P.165-71.242. Di Carlo C. Effects of sex steroid hormones and menopause on serum leptinconcentrations./ Di Carlo C., Tommaselli G. A., Nappi C. // Gynecol Endocrinol. –2002. – Vol.16(6). – P.479-491.243. Diaz-Arjonilla M. Obesity, low testosterone levels and erectile dysfunction./Diaz-Arjonilla M. [et al].// Int J Impot Res. – 2009. – Vol.21. – P.89–98.244. Dikalova AE. Upregulation of Nox1 in vascular smooth muscle leads to impairedendothelium-dependent relaxation via eNOS uncoupling./ Dikalova AE.
[et al] //Am JPhysiol Heart Circ Physiol. – 2010. - 299(3).278245. Doi T. Aldosterone induces interleukin-18 through endothelin-1, angiotensin II,Rho/Rho-kinase, and PPARs in cardiomyocytes./ Doi T. [et al] //Am J Physiol HeartCirc Physiol. – 2008. – Vol.295. – P.H1279–H1287246. Douglas PS, Katz SE, Weinberg EO, et al.
Hypertrophic remodeling: genderdifferences in the early response to left ventricular pressure overload./ Douglas PS, [etal]// J Am Coll Cardiol. – 1998. – Vol.32(4). – P.1118-1125.247. Dubey R.K. Sex hormones and hypertension./ Dubey RK. [et al]// CardiovascResearch. – 2002. – Vol.53(3). – P.688-708.248. Dubey RK. Estradiol inhibits smooth muscle cell growth in part by activating thecAMP-adenosine pathway./ Dubey RK. [et al]// Hypertension. – 2000. – Vol.35(1 Pt 2).– P.262–266.249. Dubey RK.
Estradiol metabolites inhibit endothelin synthesis by an estrogenreceptor-independent mechanism./ Dubey RK. [et al]// Hypertension. – 2001. –Vol.37(2Part 2). –P.640–644.250. Duerrschmidt N. Endothelin-1 induces NAD(P) H oxidase in human endothelialcells./ Duerrschmidt N. [et al]// Biochem Biophys Res Comm. – 2000. – Vol.269. –P.713-7.251. Eikelis N. Interactions between leptin andthe human sympathetic nervoussystem./ Eikelis N.
[et al]// Hypertension. – 2003. – Vol.41. – P.1072-1079.252. Eliasson M. Increased levels of tissue plasminogen activator antigen in essentialhypertension. A population-based study in Sweden./ Eliasson M. [et al]// J Hypertens. –1997. – Vol.15(4). – P.349-56.253. Elliot S.J. Gender-specific effects of endogenous testosterone: female a-estrogenreceptor-deficient C57BI/6J mice develop glomerulosclerosis./ Elliot S.J. [et al]//Kidney Int.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
